Angiogenic gene therapy

Drugs of Today

Volumn 38, Issue 12, 2002, Pages 819-827

  Sylvén, Christer ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALGINIC ACID; ANGIOPOIETIN; FIBRIN; FIBROBLAST GROWTH FACTOR 4; GROWTH FACTOR; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ANGIOGENESIS; CELL GROWTH; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMID; REVIEW; SLOW RELEASE FORMULATION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CLINICAL TRIALS; CORONARY VESSELS; ENDOTHELIAL GROWTH FACTORS; GENE THERAPY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; PATENTS; REGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037004364     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2002.38.12.820100     Document Type: Review

References (31)

1. Anversa, P., Nadal-Ginard, B. Myocyte renewal and ventricular remodelling. Nature 2002, 415: 240-3.
2. Asahara, T., Masuda, H., Takahashi, T. et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999, 85: 221-8.
3. Jackson, K.A., Majka, S.M., Wang, H. et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001, 107: 1395-402
4. Ylä-Herttuala, S., Martin, J.F. Cardiovascular gene therapy. Lancet 2000, 355: 213-22.
5. Edelberg, J., Lee, S., Kaur, M. et al. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model. Circulation 2002, 105: 608-13.
6. Li, J., Post, M., Volk, R. et al. PR39, a peptide regulator of angiogenesis. Nat Med 2000, 6: 49-55.
7. Asahara, T., Kalka, C., Isner, J.M. Stem cell therapy and gene transfer for regeneration. Gene Ther 2000, 7: 451-7.
8. Verma, S., Wang, C.H., Li, S.H. et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106: 913-9.
9. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6: 389-95
10. Volpert, O.V., Ward, W.F., Lingen, M.W. et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996, 98: 671-9.
11. Masferrer, J.L., Koki, A., Seibert, K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci 1999, 889: 84-6.
12. Panet, R., Markus, M., Atlan, H. Bumetanide and furosemide inhibited vascular endothelial cell proliferation. J Cell Physiol 1994, 158: 121-7.
13. Schumacher, B., Pecher, P., von Specht, B.U., Stegmann, T. Induction of neoangiogenesis in ischemic myocardium by human growth factors. Circulation 1998, 97: 645-50.
14. Udelson, J.E., Dilsizian, V., Laham, R.J. et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000, 102: 1605-10.
15. Springer, M.L., Blanco-Bose, R.J., Lee, W.E., Shaw, R., Ursell, P.C., Blau, H.M. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression. Circulation 2000, 102: 898-901.
16. Takeshita, S., Tsurumi, Y., Couffinhal, T. et al. Gene transfer of naked DNA encoding for three isoform of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest 1996, 75: 487-501.
17. Tsurumi, Y., Takeshita, S., Chen, D. et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996, 94: 3281-90.
18. Giordano, F.J., Ping, P., McKirnan, M.D. et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996, 2: 534-9.
19. 165. Lancet 1996, 348: 370-4.
20. 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1999, 97: 1114-23.
21. Rajagopalan, S., Shah, M., Luciano, A., Crystal, R., Nabel, E.G. Adenovirus-mediated gene transfer of VEGF(121) improves lowerextremity endothelial function and flow reserve. Circulation 2001, 104: 753-5.
22. Makinen, K., Manninen, H., Hedman, M. et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: A randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002, 6: 127-33.
23. Mack, C.A., Patel, S.R., Schwarz, E.A. et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998, 115: 168-76.
24. Tio, R.A., Tkebuchava, T., Scheuermann, T.H. et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Ther 1999, 10: 2953-60.
25. Rosengart, T.K., Lee, L.Y., Patel, S.R. et al. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF-121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999, 100: 468-74.
26. Symes, J.F., Losordo, D.W., Vale, P.R. et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999, 68: 830-7.
27. Losordo, D.W., Vale, P.R., Hendel, R.C. et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002, 105: 2012-8.
28. Sarkar, N., Rück, A., Källner, G. et al. Effects of intramyocardial injection of phVEGF-A 165 as sole therapy in patients with refractory coronary artery disease-12-month follow-up: Angiogenic gene therapy. J Int Med 2001, 250: 373-81.
29. Vale, P.R., Losordo, D.W., Milliken, C.E. et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001, 103: 2138-43.
30. Kastrup, J., Jörgensen, E., Drvota, V. et al. Gene therapy with VEGF165 in severe ischemic heart disease. The initial safety data of the EUROINJECT ONE study. Heart Drug 2001, 1: 299-304.
31. Grines, C.L., Watkins, M.W., Helmer, G. et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002, 105: 1291-7.